Physician profile
Mark D Rupasinghe
NPI 1326624222
$2,787.17
in general payments reported to CMS, 2019-2025
11 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $655 · 2024: $893 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422 · Travel and Lodging: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.18 |
| Travel and Lodging | $238.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $941.38 | 2024-2025 | General - Interventional Oncology, Therasphere Administration Set, Embold Fibered |
| Penumbra, INC. | $686.52 | 2023-2024 | Indigo System |
| Cook Medical LLC | $552.98 | 2024-2025 | Rosch-Uchida, Zilver Ptx, Zilver Vena |
| W. L. Gore & Associates, INC. | $160.95 | 2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Viatorr Tips Endoprosthesis With Controlled Expansion |
| Acera Surgical, INC. | $126.74 | 2022 | |
| Stryker Corporation | $117.03 | 2025 | Artix Mt |
| Trisalus Life Sciences, INC. | $104.38 | 2024-2025 | Trinav Infusion System |
| Okami Medical, INC. | $33.78 | 2025 | Lobo |
| Veryan Medical Incorporated | $26.83 | 2025 | Biomimics 3d Vascular Stent System |
| Angiodynamics, INC. | $19.85 | 2024 | Alphavac |
| Shockwave Medical, INC | $16.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rupasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.